Clinical Trials
16 trialsNCT01217931 2026-01-30
Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT01130519 2025-02-21
A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02724878 2025-02-13
Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00113217 2020-09-23
Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00853021 2019-06-05
Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00782275 2018-01-24
Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00496587 2017-07-19
Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00651482 2017-04-11
Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus)
Stanford University
Phase 2 Terminated
NCT01264341 2017-02-14
Efficacy and Safety of Bevacizumab/Temsirolimus Combination to Treat Advanced Renal Cell Carcinoma
Hellenic Cooperative Oncology Group
Phase 2 Terminated
NCT00440973 2016-03-17
Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney Cancer
The Methodist Hospital Research Institute
Phase 2 Terminated
NCT00601926 2015-06-15
Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Terminated
NCT00455975 2014-12-22
High-dose Bevacizumab in Advanced Renal Carcinoma Patients
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00193154 2014-04-01
OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell Carcinoma
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00301990 2014-01-10
Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00873236 2013-08-12
MRI Scans of Blood Vessel Changes Caused by Bevacizumab Alone or Given Together With Interferon Alpha-2a in Treating Patients With Stage III or Stage IV Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00323739 2013-07-26
Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma
SCRI Development Innovations, LLC
Phase 2 Completed